PRA International buys Spanish CRO (clinical research organisation):
This article was originally published in Clinica
Executive Summary
PRA International, the McLean, Virginia-based clinical research organisation (CRO), has acquired Staticon International Espana, a Madrid-based CRO, to expand its international network. Spain and Portugal are important clinical trial locations, David Thomas, vice-president and managing director of PRA's European operations told Clinica. PRA International conducts clinical trials and related services across a network of offices in the US, the UK, France, Germany, Spain and Poland. It also has partnerships in Latin America, South Africa, Australia and Asia. Of the $138 million revenues it expects in 2002, around 40% will be derived from its multi-country clinical trials. PRA also offers a number of complementary activities, including digitisation of medical images and specialised testing.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.